How to access Skyclarys from India, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient (or a young adult supported by their family) diagnosed with Friedreich's ataxia may receive a prescription for Skyclarys (omaveloxolone) from their treating neurologist. Skyclarys is FDA-approved as the first therapy specifically indicated for Friedreich's ataxia, developed by Reata Pharmaceuticals (later acquired by Biogen). Friedreich's ataxia is a rare, progressive, inherited neurological disease, and Skyclarys is, at present, the only disease-modifying therapy available anywhere in the world for this population. In India, Skyclarys may not be registered with CDSCO (we confirm its current CDSCO status for your case at intake), which is why your neurologist will navigate the named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Skyclarys in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Skyclarys is a small-molecule Nrf2 pathway activator, taken as an oral capsule once daily. Eligibility is based on a confirmed diagnosis of Friedreich's ataxia, typically genetic confirmation of pathogenic variants in the FXN gene. Your neurologist will confirm diagnosis, baseline neurological function (for example using standard ataxia rating scales), and set up monitoring, liver enzymes, BNP, lipid profile, and ataxia assessment, per FDA labeling. Because Skyclarys is oral, in-country infrastructure requirements are modest once the prescribing team has the monitoring plan in place.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Skyclarys legally importable into India?
Yes, through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. India has a well-established personal-use import mechanism that is regularly used for rare-disease therapies, including those with no locally registered alternative. The route permits a registered medical practitioner, or, for personal use, the patient with physician documentation, to request import of a medicine approved by a recognised reference authority (FDA qualifies) where no clinically equivalent registered alternative exists. For Friedreich's ataxia in India, there is no locally registered disease-modifying alternative, which makes the clinical rationale straightforward to articulate.
How the pathway works, step by step
- Consultation with your treating neurologist. Genetic confirmation of Friedreich's ataxia and a written clinical rationale documenting the absence of locally registered alternatives.
- Baseline assessment. Liver enzymes, BNP, lipid panel, and an ataxia rating scale measurement are recorded.
- CDSCO personal-use / named-patient application. The physician or hospital files the application with clinical rationale, genetic report, patient identification, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Skyclarys from authorised distribution.
- Ambient shipment. Skyclarys capsules ship at ambient controlled conditions, with chain-of-custody documentation and customs clearance support.
- Arrival and dispensing. The hospital pharmacy (or licensed personal-use receiver) releases the bottle to the patient with neurology-guided monitoring schedule.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming Friedreich's ataxia diagnosis, genetic report, and Skyclarys as the indicated treatment
- Verification of their Indian medical registration (MCI / NMC)
- A copy of the FXN genetic diagnostic report
- Patient identifier and address for the import record
- Planned dosing schedule and safety monitoring plan (LFTs, BNP, lipid profile, ataxia scale)
Reserve Meds provides a physician documentation kit that bundles the templates CDSCO reviewers and Indian customs expect to see for rare-disease named-patient and personal-use imports.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. Friedreich's ataxia is typically a long-term therapy. International logistics, customs clearance, CDSCO documentation handling, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling basis against your monthly schedule.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: Friedreich's ataxia often affects young adults, and Indian families commonly take shared responsibility for long-term care decisions across generations and continents. Our case lead coordinates with whichever family members, a parent in Bangalore, a sibling in Chicago, an uncle in Dubai, the patient designates.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Skyclarys specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for CDSCO / customs review.
- Logistics. International shipment with chain-of-custody and customs clearance support.
- Dedicated case lead. A named point of contact for the family wherever they are based, including long-term refill coordination.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. Cross-border import for rare-disease therapies with no local alternative is a well-established mechanism. See our trust and compliance page.
Is Skyclarys a cure? Skyclarys is a disease-modifying therapy intended to slow the progression of neurological decline in Friedreich's ataxia. It is not a cure. Your neurologist will discuss realistic outcome expectations.
How long will my family member need to stay on therapy? Chronic rare-disease therapies are typically continued indefinitely while the patient is benefiting and tolerating treatment. Annual cost and refill planning are part of the case-lead relationship.
Can the family abroad pay directly? Yes. Cross-border payment is common for rare-disease care supported by diaspora family, and we issue invoicing that family members in the US, UK, UAE, Canada, and Australia can settle directly.
Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Skyclarys coordination in India, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Skyclarys in India if it is not approved or available there?
Reserve Meds coordinates US-sourced Skyclarys for patients in India through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for India and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Skyclarys in India through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Skyclarys. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in India, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Skyclarys in India through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Skyclarys to a patient in India?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Skyclarys to your treating physician or hospital pharmacy in India, with appropriate handling for the product.
How long does it take, and what does Skyclarys in India cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Skyclarys in India?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.